Introduction
Peripartum cardiomyopathy (PPCM) is a cardiomyopathy of unknown cause with left ventricular systolic dysfunction towards the end of pregnancy or in the first months after delivery. It is a diagnosis of exclusion in women with no pre-existing heart disease or any other cause of heart failure. Left ventricular ejection fraction (LVEF) is nearly always reduced below 45%.
United States, 8 1:5719 deliveries in Sweden, 17 and the lowest reported incidence of 1:20 000 deliveries in Japan. 9 The majority of patients recover left ventricular function, 10, 11 but substantial mortality and morbidity rates remain: reported mortality rates range between 0.5 − 16.5% 10 -14 and persistent heart failure has been reported among 6-25%. 10, 11, 14 The EURObservational Research Programme (EORP) has started a worldwide prospective PPCM registry, 15 now with more than 500 women enrolled from 43 countries (EORP PPCM newsletter, July 2016). From Europe, there have been reports from a German prospective PPCM registry based on physicians' reports, 11 a small Irish single-centre cohort 16 and, most recently, a nationwide Swedish registry study, 17 but population-based estimates of incidence and outcome from Europe are few. Therefore, we aimed to estimate the nationwide incidence and outcome of PPCM in Denmark during 1994-2015.
Methods

Data sources
The Danish National Patient Register, Medical Birth Register and Causes of Death Register were searched to identify women with PPCM in the period from 1 January 2005 through 31 December 2014. The National Patient Registry contains administrative and clinical information on all hospital discharge diagnoses assigned in Denmark since 1977. From 1995 and onwards, information on all outpatient activities and emergency room diagnoses are also included. Since 1994, diagnostic information has been coded according to the International Classification of Diseases, version 10 (ICD-10). 18 The Medical Birth Register has recorded detailed information on all live births and stillbirths in Denmark since 1973, 19 and the Causes of Death Register contains death certificate information including contributing and underlying causes of death from 1970 and onwards. 20 All information in the registries above is recorded using the unique personal identification number that all Danish citizens have been assigned since 1968, 18 which allows linkage between registries and subsequent identification and auditing of clinical patient records.
Study population
First, we searched the National Patient Register for all women assigned the ICD-10 specific diagnosis O90.3 (PPCM) in the study period. Second, we cross-linked the National Patient, the Medical Birth, and the Causes of Death Registries to identify all births in the study period (n = 619 084) and considered all women assigned a diagnosis of heart failure (I50 and O75.4) or cardiomyopathy (I42 and I43) either at discharge or in fatal cases at the death certificate in a period of nine months prior to giving birth to 12 months postpartum eligible for inclusion.
Validation of peripartum cardiomyopathy diagnosis and outcomes
We retrieved and reviewed patient records for all eligible women from a total of 17 hospitals, and included only women who met the EORP PPCM registry's inclusion criteria: age ≥18 years, unexplained heart failure developed towards the end of pregnancy or in the first six (Figure 1 ). This 10-year period was chosen as we did not consider it possible to retrieve sufficient data from older patient records.
Additional baseline and outcome data including demographics, medical history, pregnancy and delivery information, clinical presentation, timing of PPCM diagnosis, baseline and follow-up LVEF as close to 12 months after diagnosis as possible, clinical management strategies, medical therapy and major adverse cardiac events including death, heart transplantation and mechanical circulatory support (MCS) requirement, were obtained from the patient records. Information on in-hospital treatment with the dopamine receptor agonists bromocriptine and cabergoline, that both inhibit pituitary prolactin secretion, was collected. Bromocriptine has been suggested to improve outcome in PPCM, 5, 11, 21 whereas cabergoline may be prescribed to inhibit lactation. Complete recovery was defined by LVEF ≥55% after 12 months or at last available follow-up before 12 months. Any improvement was defined as LVEF ≥50% after 12 months, or 12-month follow-up LVEF between 35% and 50% and >10% improvement in LVEF from baseline. Hypertensive disorders of pregnancy included chronic and gestational hypertension and pre-eclampsia. Gestational hypertension was defined as onset of hypertension beyond 20 weeks of gestation with systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg and no significant proteinuria, whereas pre-eclampsia was defined as onset after 20 weeks of gestation of SBP ≥140 mmHg or DBP ≥90 mmHg and significant proteinuria (>0.3 g/24 h or ≥1+ on sterile urine dipstick). Early-onset pre-eclampsia presented at 34 weeks of gestation or earlier. 22 Postpartum haemorrhage was defined as >500 mL blood loss at delivery. Small for gestational age was defined as a birth weight <10th percentile and intrauterine growth restriction as <2.3rd percentile. 23 
Statistical analysis
All data are presented as means ± standard deviations for continuous variables and as proportions for categorical variables. Continuous and categorical variables were compared between women with and without complete recovery and with and without HDP using Student's t-test for normally distributed continuous variables and chi-square test or Fisher's exact test for categorical variables as appropriate.
In order to assess possible predictors of recovery, six candidate variables were predefined based on previous studies, 9 -11,14,21,24 or because they indicate disease severity: body mass index (BMI, kg/m 2 ), timing of diagnosis (number of days before or after delivery), HDP, baseline LVEF (%), need for inotropic therapy and/or MCS, and prolactin inhibition with either bromocriptine or cabergoline.
The effect of the candidate variables on the dichotomous outcome of complete recovery was assessed in a multiple logistic regression analysis. To evaluate predictors of the continuous outcome LVEF at 10-14 months after the initial PPCM diagnosis, we performed univariable and multiple linear regression analyses including the six candidate variables listed above. Also, three unplanned analyses were performed: a multiple linear regression analysis including variables with P < 0.15 in univariable analysis, a comparison of clinical characteristics between women with a baseline LVEF ≤25% categorized by dobutamine or not, and a comparison of characteristics in the total cohort categorized by cabergoline or not. In all analyses, a P-value of <0.05 was considered to be significant.
All statistical analyses were performed using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA). 
Results
During the 10-year study period (2005-2014), we searched 619 084 deliveries and identified 219 women who had been assigned a ICD-10 PPCM, another cardiomyopathy and/or heart failure diagnosis in temporal relation to a delivery and hence met the eligibility criteria, equalling 1:2872 deliveries. Out of these, we retrieved 207 records (94.5%) and identified 61 women who met the EORP PPCM registry's inclusion criteria, equalling 1:10 149 deliveries. The remaining 146 women had other (pre-existing) heart diseases or specific cardiomyopathies (n = 85), had been clinically evaluated but not determined to have a heart disease (n = 32), or had been wrongly assigned a diagnosis of heart failure or cardiomyopathy (n = 29) (Figure 1) . The distribution of the diagnostic codes among the 219 eligible women screened for inclusion and the 61 women in the final cohort is presented in the Supplementary material online ( Table S1 ). The code O90. temporal relation to a delivery identified 45 women (73.8%) of the final cohort, but only 39.5% of all women assigned this diagnosis were included, proving lower validity for this code. Baseline and management characteristics of the 61 women with PPCM, overall and with regard to complete recovery or not, are presented in Table 1 . The mean age was 31.7 ± 6.3 years. A total of six women (9.8%) were confirmed non-Caucasians (one black, three Asian and two Greenlandic Inuit women). The mean duration from delivery to diagnosis was 25 ± 44 days. Almost a quarter (22.9%) had postpartum haemorrhage (blood loss >500 mL) with a mean blood loss of 1205 mL (range 550-2500 mL), and seven women (11.5%) had a major postpartum haemorrhage with a blood loss of ≥1000 mL. More than half of the women (54.1%) had HDP in the index pregnancy. A total of 32 women (52.5%) recovered completely, and women who recovered completely had significantly more twin pregnancies, more often HDP, more often treatment with labetalol during pregnancy, a higher caesarean section rate, a higher baseline LVEF, and higher SBP and DBP at presentation. The majority of women were treated with a beta-blocker and an angiotensin-converting enzyme inhibitor after PPCM diagnosis, and 39.3% received 0.50 mg cabergoline for two days with the intention of inhibiting lactation. Cabergoline therapy did not differ significantly between women who recovered completely and those who did not (P = 0.074). None were treated with bromocriptine. In Values are expressed as mean ± standard deviation, or number (%). Complete recovery is defined by LVEF ≥55% after 12 months or last follow-up before 12 months (range 3-12 months). ACE, angiotensin-converting enzyme; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; PPCM, peripartum cardiomyopathy; SBP, systolic blood pressure. * Co-morbidities: asthma (6), thyroid disorders (3), chronic hypertension (2), depression (2), epilepsy (2), rheumatoid arthritis (2), ADAMTS13 deficiency (1), antiphospholipid syndrome (1), Crohn's disease (1), and factor V Leiden mutation (1). † Inotropic therapy: dobutamine (7), levosimendan (6) and milrinone (4). # MCS: HeartMate II left ventricular assist device (2), Levitronix left ventricular assist device (1), Impella left ventricular assist device (1), and extracorporeal membrane oxygenation (1).
a subanalysis, complete recovery was defined as LVEF ≥50%, which entailed a complete recovery rate of 67.2%. Baseline characteristics did not change importantly with this definition. Table 2 presents characteristics and outcome with regard to concomitant HDP or not. The majority of women, both with and without HDP, had improved LVEF at follow-up (93.9% and 78.6%, respectively). Women with HDP had a higher mean LVEF at 12-month follow-up, were more often primiparous, had shorter duration of pregnancy, higher SBP and DBP at PPCM diagnosis, higher baseline LVEF, shorter duration of admissions, less need for inotropic therapy and/or MCS, and no major adverse events.
A total of nine women (14.8%) had one or more major adverse cardiac event (3.3% mortality, 8.2% mechanical circulatory support requirement and/or heart transplantation and 4.9% persistent severe heart failure at 10-14 months after diagnosis) (Figure 2) . two heart transplantations were performed 23 and 165 days after the initial diagnosis, respectively. Out of 32 women who had a baseline LVEF ≤25%, a total of six women were treated with dobutamine. These six women had significantly lower baseline LVEF and accounted for more major adverse cardiac events than the 26 women to whom dobutamine was not administered (see Supplementary material online, Table S2 ).
Neonatal outcome for the 66 live-born babies is presented in Table 3 . There was one neonatal death that was a result of complications of prematurity and 30.3% were delivered preterm. A total of 18 babies (27.3%) were small for gestational age and four babies (6%) had a congenital cardiovascular malformation.
In the multiple logistic regression analysis of complete recovery including all six candidate variables, cabergoline therapy was the only significant predictor of recovery [adjusted odds ratio (OR) 4.64, 95% confidence interval (CI) 1.18-18.24; P = 0.028] ( Table 4) . prescription of guideline heart failure therapy 25 differed significantly between women who were prescribed cabergoline and women who were not: mean LVEF was 26.2% and 27.0%, respectively (P = 0.73), both a beta-blocker and an ACE-inhibitor were prescribed to 75.0% and 73.0%, respectively (P = 0.86), and both a beta-blocker, an ACE-inhibitor and a mineralocorticoid receptor antagonist were prescribed to 41.7% and 59.7%, respectively (P = 0.34) (see Supplementary material online, Table S3 ).
A total of 43 women (70%) had an available follow-up LVEF assessment 10-14 months after the initial diagnosis. The remaining 18 women either had an adverse outcome or no LVEF report was available within 10-14 months. Univariable and multiple linear regression analysis of the continuous outcome follow-up LVEF is presented in Table 5 . Only baseline LVEF proved to be significant in the univariable analyses (P = 0.002), but five other predefined candidate variables (BMI, age, timing of diagnosis, HDP and cabergoline therapy) were included in the multiple linear regression analysis to assess if the effect of baseline LVEF was attenuated. Baseline LVEF remained the only significant predictor (P = 0.0086). A sensitivity analysis excluding cabergoline from the model did not change this. In a multiple linear regression analysis including variables with P < 0.15 in univariable analysis (baseline LVEF, BMI, non-Caucasian ethnicity and HDP), baseline LVEF remained a significant predictor with the addition of the non-validated variable non-Caucasian ethnicity. Exclusion of non-Caucasian ethnicity did not change the result (analysis not shown).
Discussion
In this first European nationwide cohort study with chart review and validation of the diagnosis, we identified 61 women with PPCM according to the EORP PPCM Registry's inclusion criteria, equalling an incidence 9 This difference may, at least in part, be explained by the low prevalence of black women in our cohort compared to other cohorts. 26, 27 Black race has previously been found to be associated with an increased risk of developing PPCM and a subsequent poorer prognosis. 10, 26 Sweden and Denmark are demographically comparable, and the difference in estimated incidences between the recent Swedish study where Barasa et al. found PPCM in 1:5719 deliveries and this study may be explained by differences in search criteria and lack of chart review in the Swedish study.
17
Despite a lower incidence, outcomes in this cohort are similar to outcomes in several other cohorts: major adverse cardiac events including mortality and persistent severe heart failure with LVEF <35% were noted among 13% and complete recovery defined as LVEF ≥50% was obtained by 72% of the women in the prospective IPAC study assessing outcomes after 12 months. 10 In our study, 53% reached a LVEF ≥55%, which is comparable to the finding in a German cohort where 47% reached complete recovery defined as LVEF ≥55% after 6 ± 3 months and 15% failed to recover with 2% mortality.
11 Mortality was 4%, MCS requirement 2% and complete recovery defined as LVEF >50% was 63% after 6 months in a Japanese cohort. 9 The finding of baseline LVEF as a robust predictor of LVEF after 12 months 10 -14 is also in accordance with previous studies. 9, 11, 14, 28 McNamara et al. did not confirm this in their adjusted analysis of predictors in the IPAC cohort, where left ventricular end-diastolic diameter was more predictive of full recovery. 10 We did not have enough data to analyze left ventricular end-diastolic diameter or other echocardiographic measurements than LVEF in this retrospective study.
Pre-eclampsia and hypertension (HDP) are strongly associated with PPCM, but may also cause asymptomatic cardiac dysfunction or heart failure with preserved ejection fraction. 29 On the other hand, PPCM often develops without preceding pre-eclampsia, and PPCM should not be viewed merely as a complication of pre-eclampsia. In this cohort, more than half had HDP in the index pregnancy and women with concomitant HDP seemed to represent a subset of women with a better prognosis, which is in line with some studies, 9,11,30,31 while others did not find hypertension or pre-eclampsia to be prognostic. 10, 28 It has been suggested to exclude women with HDP from the unexplained PPCM group, 31 but as long as the impact on clinical management and prognosis is not fully elucidated it seems reasonable to include women with concomitant HDP in future PPCM studies with attention towards differences between subgroups. Besides the presence of HDP, genetic profiles also differ between PPCM patients, and mutations in the myofibrillar protein titin have been found to be associated with a significantly lower LVEF at one-year follow-up. prove useful in the clinical management and when advising about future pregnancies. Significantly more of the women who recovered left ventricular function completely obtained the combined alfa-and beta-blocker labetalol as an antihypertensive during pregnancy. It is intriguing to speculate that this early beta-blockade and not just the HDP itself may affect PPCM prognosis. In Denmark, methyldopa has traditionally been the first choice of oral medication to treat HDP, whereas labetalol traditionally has been used for short-term treatment or to lower blood pressure acutely, but we do not have sufficient data on dosage and duration of therapy to analyze this further. The topic should be addressed in future studies.
Cabergoline and bromocriptine are both dopamine agonists that inhibit pituitary prolactin secretion. In this study, cabergoline was administered as 0.25 mg twice daily for two days only to inhibit lactation and not as a PPCM-specific treatment. Women prescribed cabergoline did not seem to represent a subgroup with more severe disease nor were they more frequently prescribed guideline medical heart failure therapy, which diminishes the risk of confounding by indication. The finding of cabergoline therapy and the following cessation of breastfeeding being a predictor of recovery in the logistic regression analysis should be interpreted with caution since we did not have any information on breastfeeding or cabergoline prescribed outside the hospital by family physicians. Also, conflicting results in the linear and logistic regression analyses limit the significance of this finding. finding that prolactin inhibition improves maternal outcome 11, 21 and calls for further research. We found a relatively high incidence of postpartum haemorrhage (22.9%) and major postpartum haemorrhage (11.5%) compared to the background population (2-7% depending on the definition). 32, 33 Pre-eclampsia is a known risk factor for postpartum haemorrhage 32 and half of the women who had a postpartum haemorrhage in our cohort had HDP, which in part explains the high incidence. However, postpartum haemorrhage itself may also stress the cardiovascular system through hypovolaemia and anaemia and add to the development of heart failure. Anaemia has previously been identified as a risk factor in PPCM patients, 12, 26 , and Kao et al. hypothesize that anaemia, in addition to other risk factors, may lead to the development of PPCM. 26 We did not have enough data on haemoglobin levels to report on this possible association, but the finding is further supported by Stapel et al., who suggest that haemorrhage leads to hyperosmolarity and subsequently reduced expression of cardiac STAT3, which protects the heart against oxidative stress and may play a role in the PPCM pathogenesis. 5, 34 Stapel et al. also reported that low STAT3 expression sensitizes to toxic effects of the beta-adrenergic receptor agonist dobutamine, and found worse outcome among women with a low baseline LVEF (≤25%) and dobutamine treatment compared with women with a correspondingly low baseline LVEF and no dobutamine treatment. 34 We performed similar analyses with similar findings, but the women who were treated with dobutamine in our study had a significantly lower mean baseline LVEF, which could explain some of the differences in outcome. This was not the case in the study by Stapel et al. where mean baseline LVEF was similar between groups. Still, the use of beta-adrenergic receptor agonists in PPCM and cardiogenic shock is associated with adverse outcome and should be avoided or used with extreme caution as recently outlined by Bauersachs et al. 35 Previous reports on neonatal outcomes are few. 28, 36 The high proportion of women with concomitant HDP may explain the relatively large proportion of preterm delivery and newborns with a low birth weight in this and other cohorts. 36 Strengths of this study are the combined approach using both population-based registries and chart review for validation of diagnosis. We used a broad range of ICD-10 codes and a broad period of time before and after delivery to identify women eligible for chart review and possible inclusion. We further refined the selection by validating the diagnosis according to the inclusion criteria of the EORP PPCM registry. The inability of a single diagnostic ICD-10 code to identify all women with validated PPCM in our cohort and the overestimation of incidence based on assigned diagnostic codes only underline the strength of this combined approach. The risk of reporting and selection bias incorporated in surveys, single-centre and other non-population-based studies is minimal, but a risk of overlooking milder cases still exists, regardless of the study approach, potentially resulting in an underestimation of the true incidence. Out of 219 eligible women, records from 12 women could not be identified. This may imply a risk of underestimation of the real prevalence of at least 5%. Also, it is possible that a proportion of women with PPCM suffered sudden cardiac death before they were diagnosed. This was the case in an American cohort of 85 women, where seven cases (8.2%) were diagnosed only at autopsy. 13 We searched the Causes of Death Register, which did not uncover any additional cases to the cohort already identified in the other registries, but in cases where autopsies were not performed, the actual cause of death may not have been reported to the registry.
The retrospective study design entails limitations such as unavailable, incomplete or missing data. We were unable to retrieve enough detailed echocardiographic reports or blood analyses from the validated cohort to assess and evaluate the impact of these important measures. Furthermore, ethnicity was only reported in a few records and in these cases only when the woman was not Caucasian. We did not find these random reports sufficient or valid enough to include the well-known risk factor of ethnicity in the planned multiple regression analyses. The relatively small number of women in our study implies a risk of overestimation of effects and the finding of prolactin inhibition being a predictor of recovery should be confirmed in larger studies.
In conclusion, the first population-based European estimate of PPCM incidence is at least 1 in 10 149 deliveries, which places Denmark between American and Japanese estimates. Clinical outcomes in the cohort were similar to those reported in recent American and European cohorts. The majority of women recovered left ventricular function within one year, but a significant proportion had a concomitant HDP and this subgroup had a milder course of the disease with a higher recovery rate, higher LVEF at follow-up and no major adverse cardiac events recorded. Baseline LVEF was the only significant predictor of LVEF 10-14 months after diagnosis, whereas cabergoline therapy to inhibit lactation predicted the dichotomous outcome of complete recovery (LVEF ≥55%). Future studies should further assess the impact of breastfeeding and prolactin inhibition and explore individual risk factors such as genetics and concomitant HDP's importance for prognosis, management strategies and risks associated with subsequent pregnancies.
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